Phytopharm plc Stock London S.E.
Stocks
GB0006869720
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| 07-13 | Oil rises as Iran escalation keeps FTSE subdued | AN |
| 07-13 | Ixico notes ending of Huntington's disease programmes | AN |
| Market Cap | 16.35M 22.08M 19.11M 18.04M 30.69M 2.11B 30.92M 215M 82.54M 1.07B 82.84M 81.08M 3.41B | P/E 2026 * |
-5.36x | P/E 2027 * | -5.77x |
|---|---|---|---|---|---|
| Enterprise Value | 6.15M 8.31M 7.19M 6.79M 11.55M 794M 11.63M 81.04M 31.06M 404M 31.17M 30.51M 1.28B | EV / Sales 2026 * |
0.77x | EV / Sales 2027 * | 1.14x |
| Free-Float |
89.22% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Phytopharm plc
| Manager | Title | Age | Since |
|---|---|---|---|
Bram Goorden
CEO | Chief Executive Officer | 53 | 2024-08-18 |
Grant Nash
DFI | Director of Finance/CFO | 50 | 2019-08-20 |
Mark Austin
CTO | Chief Tech/Sci/R&D Officer | - | 2025-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Warne
CHM | Chairman | 51 | - |
Grant Nash
BRD | Director/Board Member | 50 | 2019-08-20 |
Katherine Rogers
BRD | Director/Board Member | 60 | 2022-01-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.56% | -5.82% | -2.45% | +9.99% | 45.48B | |
| +0.66% | -2.34% | +340.62% | +524.38% | 43.68B | |
| +1.49% | -0.78% | +41.90% | +22.65% | 43.09B | |
| +2.11% | -1.24% | +9.09% | +76.85% | 39.4B | |
| +0.34% | -4.94% | +9.34% | +40.23% | 31.91B | |
| +0.53% | -2.08% | - | - | 17.31B | |
| +1.34% | +0.70% | +21.35% | +111.39% | 16.4B | |
| +2.07% | -0.77% | +13.07% | +32.89% | 14.24B | |
| -1.85% | -5.33% | +78.63% | +34.13% | 13.28B | |
| Average | +0.81% | -2.97% | +63.95% | +106.56% | 29.42B | |
| Weighted average by Cap. | +0.94% | -3.26% | +76.00% | +126.85% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8M 10.8M 9.35M 8.83M 15.01M 1.03B 15.13M 105M 40.38M 525M 40.53M 39.66M 1.67B | 9M 12.15M 10.52M 9.93M 16.89M 1.16B 17.02M 119M 45.42M 591M 45.59M 44.62M 1.88B |
| Net income | -2.14M -2.89M -2.5M -2.36M -4.02M -276M -4.05M -28.22M -10.82M -141M -10.86M -10.62M -447M | -2.8M -3.78M -3.27M -3.09M -5.26M -361M -5.3M -36.89M -14.14M -184M -14.19M -13.89M -584M |
| Net Debt | -10.2M -13.77M -11.92M -11.25M -19.14M -1.32B -19.29M -134M -51.48M -670M -51.67M -50.57M -2.13B | -6.1M -8.24M -7.13M -6.73M -11.45M -787M -11.53M -80.34M -30.79M -400M -30.9M -30.24M -1.27B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
